INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)
SHEET 1 OF 1

ì				U.S. PATENT DOCUMENTS				
Charles of the Control of the Control	Examiner Initials	Cite No.	Document Number Number - Kind Code (If known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear		

			FOREIGN PATE	NT DOCUMENTS	-	
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Υ1

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹				
	1	CHENGAPPA, et al. 'Changes in body Weight and Body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review' Clinical Therapeutics, 24 (10) 1576-1584 (2					
	2	HAHN, et al. J. Pharm Exper. Therapeutics 235:846-850. (1985)					
	3	Vieta, et al. 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry 64(7):834-839 (2003)					
	4	Vieta, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. Journal of Clinical Psychopharmacology 24(4):374-378 (2004)					

4935469 kjw 022608

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.